WallStreetZenWallStreetZen

NASDAQ: FRTX
Fresh Tracks Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

FRTX past revenue growth

How has FRTX's revenue growth performed historically?
Company
1,332.15%
Industry
69.59%
Market
14.15%
FRTX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
FRTX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
FRTX's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

FRTX earnings and revenue history

Current Revenue
$6.9M
Current Earnings
-$16.0M
Current Profit Margin
-232.8%

FRTX Return on Equity

Current Company
-145.4%
Current Industry
-18%
Current Market
30.8%
FRTX's Return on Equity (-145.4%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when FRTX announces earnings.

FRTX Return on Assets

Current Company
-115.7%
Current Industry
0.9%
FRTX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

FRTX Return on Capital Employed

Current Company
-161.77%
Current Industry
14.1%
FRTX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

FRTX vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
FRTX$6.86M-$15.84M-$15.97M-9.55%N/A
RNAZ$0.00-$18.73M-$18.91MN/AN/A
HSTO$19.00k-$13.27M-$13.91M-78.15%N/A
PBLA$0.00-$36.08M-$36.38MN/AN/A
BXRX$848.00k-$33.10M-$34.58M+10.78%N/A
View Top Biotech Stocks

Fresh Tracks Therapeutics Earnings & Revenue FAQ

What were FRTX's earnings last quarter?

On Invalid Date, Fresh Tracks Therapeutics (NASDAQ: FRTX) reported Q1 2023 earnings per share (EPS) of -$1.14, up 67.89% year over year. Total Fresh Tracks Therapeutics earnings for the quarter were -$4.28 million. In the same quarter last year, Fresh Tracks Therapeutics's earnings per share (EPS) was -$3.55.

If you're new to stock investing, here's how to buy Fresh Tracks Therapeutics stock.

What was FRTX's earnings growth in the past year?

As of Q2 2023, Fresh Tracks Therapeutics's earnings has grown year over year. Fresh Tracks Therapeutics's earnings in the past year totalled -$15.97 million.

What was FRTX's revenue last quarter?

On Invalid Date, Fresh Tracks Therapeutics (NASDAQ: FRTX) reported Q1 2023 revenue of $9.00 thousand up 90.22% year over year. In the same quarter last year, Fresh Tracks Therapeutics's revenue was $92.00 thousand.

What was FRTX's revenue growth in the past year?

As of Q2 2023, Fresh Tracks Therapeutics's revenue has grown 1,332.15% year over year. This is 1,262.56 percentage points higher than the US Biotechnology industry revenue growth rate of 69.59%. Fresh Tracks Therapeutics's revenue in the past year totalled $6.86 million.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.